An American Medical Association survey of 1000 physicians regarding the impact of prior authorization (PA) found that most providers reported a significant or negative impact on patient care, and more than a quarter reported a serious adverse event.
An American Medical Association (AMA) survey of 1000 physicians regarding the impact of prior authorization (PA) found that most providers reported a significant or negative impact on patient care, and more than a quarter reported a serious adverse event (AE).
Serious AEs—death, hospitalization, disability, permanent body damage, or other life-threatening complication—were reported by 28% of respondents, and more than 9 in 10 respondents said PA had a significant or somewhat negative clinical impact.
The web-based survey was conducted in December 2018 and was answered by specialists (60%) and primary care physicians (40%).
The use of PAs has long been a concern of the AMA; according to the organization, utilization management programs—including PAs and step therapy—can create significant barriers for patient-centered care, as the manual, time-consuming processes often used in these programs place additional burdens on providers and direct resources away from patient care.
In the 2018 survey, doctors said that they or their staff spent 2 working days each week completing PAs, and 36% have staff whose sole job is to work on PAs. On average, practices complete 31 PAs per provider per week.
Not surprisingly, 86% of physicians reported that PAs created a high or extremely high burden for the office. In addition, 88% said the burden has increased over the last 5 years.
Other findings of the survey include:
The AMA noted that, traditionally, insurers applied PA to newer, more expensive services and medications. But in recent years, physicians have reported an increase in the volume of PAs.
For instance, at a 2017 annual meeting of the American College of Rheumatology, clinicians noted that PAs were increasing not only for expensive biologics to treat rheumatic diseases, but also for older, less-expensive medications such as steroid therapies or methotrexate. One presenter said the increasing volume of specialty drug prescriptions, steeper renewal requirements, insurance expansion, new therapeutics, and formulary updates were all factors behind the increased volume.
“The AMA survey continues to illustrate that poorly designed, opaque (PA) programs can pose an unreasonable and costly administrative obstacle to patient-centered care,” said AMA Board of Trustees Chair Jack Resneck Jr., MD, in a statement.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
2 Commerce Drive
Cranbury, NJ 08512